Accuray Inc. (ARAY)

5.15
0.10 1.90
NASDAQ : Health Technology
Prev Close 5.25
Open 5.25
Day Low/High 5.10 / 5.30
52 Wk Low/High 3.60 / 6.15
Volume 313.04K
Avg Volume 1.34M
Exchange NASDAQ
Shares Outstanding 85.29M
Market Cap 430.73M
EPS -0.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Accuray Elects Net Share Settlement For 3.50% Series A Convertible Senior Notes Due 2018

Accuray Elects Net Share Settlement For 3.50% Series A Convertible Senior Notes Due 2018

Company will pay principal in cash and deliver shares for any excess conversion value

First Hospitals In The World Achieve Inter-System Connectivity Across Accuray Radiation Therapy Platforms

First Hospitals In The World Achieve Inter-System Connectivity Across Accuray Radiation Therapy Platforms

iDMS™ Data Management System Helps Improve Treatment Outcomes and Efficiency by Sharing Patient Data Throughout the Entire Disease Management Period

Accuray Military Veterans Support U.S. Veteran Community

Accuray Military Veterans Support U.S. Veteran Community

Advanced Radiation Therapy Systems Manufactured, Installed and Serviced by Accuray Veterans Help Improve the Lives of Military Personnel who are Diagnosed with Cancer

Treatment Planning For The CyberKnife® System Now Up To 40% Faster

Treatment Planning For The CyberKnife® System Now Up To 40% Faster

- Accuray Precision™ Treatment Planning System and CyberKnife System Software Upgrade Enhances Efficiency and Ease-of-Use

10-year Data Shows CyberKnife® System Provides Excellent Long-term Control Of Low-Risk Prostate Cancer

10-year Data Shows CyberKnife® System Provides Excellent Long-term Control Of Low-Risk Prostate Cancer

First Study to Evaluate the Use of Stereotactic Body Radiation Therapy in Low-Risk Prostate Cancer 10 Years Post Treatment

Summit Cancer Center-Boise Treats Its First Cancer Patients Using The Accuray Radixact™ System

Summit Cancer Center-Boise Treats Its First Cancer Patients Using The Accuray Radixact™ System

Freestanding Center is First in the Western U.S. to Treat Patients with this "Smart" Radiation Therapy Delivery System with Fully-Integrated Treatment Planning and Data Management Systems

Accuray Receives 510(k) Clearance For IDMS™ Data Management System Upgrade For The TomoTherapy® System

Accuray Receives 510(k) Clearance For IDMS™ Data Management System Upgrade For The TomoTherapy® System

iDMS System Allows Seamless Integration between Accuray Radixact™, TomoTherapy® and CyberKnife® Systems and Treatment Planning Systems

Accuray Enhances Capital Structure Through Convertible Debt Transactions

Accuray Enhances Capital Structure Through Convertible Debt Transactions

­Transactions Facilitate Reduction of Short-term Debt and Potential Dilution to Shareholders

New Data Show TomoTherapy® System Superior To RapidArc In Achieving Local Control Of Head And Neck Cancers

New Data Show TomoTherapy® System Superior To RapidArc In Achieving Local Control Of Head And Neck Cancers

Prospective, Multicenter Study Supported by the French National Institute of Cancer Also Demonstrates that Treatment with the TomoTherapy Platform Resulted in a Significantly Better Cancer-Specific Survival Rate and Post-Treatment Salivary Function

Accuray Announces Preliminary Fourth Quarter And Fiscal Year 2017 Results

Accuray Announces Preliminary Fourth Quarter And Fiscal Year 2017 Results

Q4 Revenue Expected to be Approximately $111.5-$112 Million and Q4 Gross Orders Expected to be Approximately $86 Million; Accuray Expects to Finish Fiscal Year with Approximately $108 Million in Cash, Cash Equivalents & Investments

Neuro Spinal Hospital In Dubai To Acquire Accuray CyberKnife® And Radixact™ Systems

Neuro Spinal Hospital In Dubai To Acquire Accuray CyberKnife® And Radixact™ Systems

Leading Hospital will be the First in the Middle East to Offer Patients Precise Treatments with the Latest Generations of Both Systems

Montefiore Is First In NY Metropolitan Area To Treat Cancer Patients With Accuray Radixact™ System

Cutting-Edge Radiation Therapy System Dramatically Improves Precision, Efficiency and Safety, While Minimizing Side Effects

IUCT Oncopole Advances Cancer Care In France With The New Accuray Radixact™ System

The French Cancer Institute is Building its Re-irradiation and Adaptive Radiotherapy Program Using the Latest Technology Developed by Accuray

Anova Marks 1,500th Prostate Cancer Patient Treated With The Accuray CyberKnife® System

- Accuray and Anova Cancer Care Remember Prostate Patients this Father's Day

Accuray Enters Into New Revolving Loan Agreement

New Loan Expected to Reduce Interest Costs by Approximately $2.0 Million Annually

Accuray Enters Oversold Territory (ARAY)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week of ARAY September 15th Options Trading

First Week of ARAY September 15th Options Trading

Investors in Accuray Inc saw new options begin trading this week, for the September 15th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 233 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Accuray Continues To Set The Industry Standard For Customer Satisfaction

Accuray Continues To Set The Industry Standard For Customer Satisfaction

MD Buyline Report Shows Composite Overall User Satisfaction Ratings Exceed Industry Average for 14 Consecutive Quarters

Short Interest Moves 12.7% Lower For ARAY

Short Interest Moves 12.7% Lower For ARAY

The most recent short interest data has been released for the 12/30/2016 settlement date, which shows a 963,627 share decrease in total short interest for Accuray Inc , to 6,615,663, a decrease of 12.71% since 12/15/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Commit To Buy Accuray At $4, Earn 11.6% Annualized Using Options

Commit To Buy Accuray At $4, Earn 11.6% Annualized Using Options

Investors eyeing a purchase of Accuray Inc shares, but cautious about paying the going market price of $5.08/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the June 2017 put at the $4 strike, which has a bid at the time of this writing of 25 cents.

Commit To Buy Accuray At $4, Earn 11.6% Annualized Using Options

Commit To Buy Accuray At $4, Earn 11.6% Annualized Using Options

Investors eyeing a purchase of Accuray Inc shares, but cautious about paying the going market price of $5.08/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the June 2017 put at the $4 strike, which has a bid at the time of this writing of 25 cents.

Commit To Buy Accuray At $4, Earn 11.6% Annualized Using Options

Commit To Buy Accuray At $4, Earn 11.6% Annualized Using Options

Investors eyeing a purchase of Accuray Inc shares, but cautious about paying the going market price of $5.08/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the June 2017 put at the $4 strike, which has a bid at the time of this writing of 25 cents.

TheStreet Quant Rating: D+ (Sell)